Vanucizumab

Tax included
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects.
MedChemExpress 
HY-P99330

Data sheet

Size
Multiple sizes
Reactivity
VEGFR; Tie2
Application
Cancer-Kinase/protease
CAS
1448221-05-3